ImmuCell Corporation (ICCC) has a negative trailing P/E of -63.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -1.57%.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 49.5 | -0.71 | 1.27 | 2.63 | - |
| 2017 | -258.9 | 2.02 | 1.84 | 4.17 | - |
| 2018 | -16.6 | -0.01 | 1.78 | 3.52 | - |
| 2019 | -27.1 | 0.49 | 1.21 | 2.56 | - |
| 2020 | -42.0 | 1.60 | 1.52 | 2.80 | - |
| 2021 | -775.8 | 8.37 | 1.86 | 3.16 | - |
| 2022 | -18.9 | -0.01 | 1.56 | 2.54 | - |
| 2023 | -6.8 | -0.05 | 1.57 | 2.24 | - |
| 2024 | -19.5 | 0.30 | 1.53 | 1.59 | - |
| 2025 | -53.4 | 0.99 | 2.05 | 2.01 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $0.12 | $9.54M | $508.45K | 5.3% |
| 2017 | $-0.03 | $10.43M | $-168K | -1.6% |
| 2018 | $-0.42 | $10.99M | $-2.32M | -21.1% |
| 2019 | $-0.19 | $13.72M | $-1.3M | -9.4% |
| 2020 | $-0.14 | $15.34M | $-1.02M | -6.7% |
| 2021 | $-0.01 | $19.24M | $-78K | -0.4% |
| 2022 | $-0.32 | $18.57M | $-2.49M | -13.4% |
| 2023 | $-0.75 | $17.47M | $-5.77M | -33.1% |
| 2024 | $-0.26 | $26.49M | $-2.16M | -8.1% |
| 2025 | $-0.12 | $27.64M | $-1.04M | -3.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.24 | $-0.24 – $-0.24 | $15.14M | $15.14M – $15.14M | 1 |
| 2027 | $-0.11 | $-0.11 – $-0.11 | $19.2M | $19.2M – $19.2M | 1 |
